The patent system belongs to the American people and exists for our benefit. It’s been critical to spurring valuable innovation in medicine — but unfortunately there exist a number of loopholes that drug companies regularly exploit to abuse the patent system and maintain monopoly prices for their drugs.
Take Humira, Abbvie’s brand-name drug to treat rheumatoid arthritis, for example: Humira cost $523 per month in 2002. In 2023, it costs $3,167 per month.
This month, the U.S. Senate is considering different health care cost solutions. They need to hear from you that it’s important to end drug patent abuse tactics and help generics reach pharmacy shelves. You can make a difference right now by sending an urgent message to your U.S. senators supporting strong federal-level reforms to the patent system.